Evidence map›Paper›PMID 40560613›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1-WAVE2 interaction.

Matthias Müller, Matthias Barone, Maarten van Dinther, Kathrin Motzny, Jiang Ren, Jenny Eichhorst, Dominik Albat, Slim Chiha, Martin Lehmann, Rudolf Volkmer and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matthias Müller *PROSION Therapeutics, Köln 50931, Germany.ORCID 0009-0008-4933-1077
Matthias Barone *Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.ORCID 0000-0002-6554-6464
Maarten van DintherOncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden 2333, The Netherlands.ORCID 0000-0002-9451-8884
Kathrin MotznyLeibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.
Jiang RenOncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden 2333, The Netherlands.
Jenny EichhorstLeibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.ORCID 0009-0002-6013-736X
Dominik AlbatPROSION Therapeutics, Köln 50931, Germany.
Slim ChihaPROSION Therapeutics, Köln 50931, Germany.
Martin LehmannLeibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.ORCID 0000-0002-8370-6353
Rudolf VolkmerLeibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.
Hartmut OschkinatLeibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.ORCID 0000-0002-4384-9544
Hans-Günther SchmalzPROSION Therapeutics, Köln 50931, Germany.ORCID 0000-0003-0489-1827
Peter Ten DijkeOncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden 2333, The Netherlands.ORCID 0000-0002-7234-342X
Ronald KühnePROSION Therapeutics, Köln 50931, Germany.ORCID 0009-0008-7498-6489

Funding

Bundesministerium für Bildung und Forschung (BMBF) 16GW0186KEC | Horizon Europe | | HORIZON EUROPE European Innovation Council (EIC) 190154511Health~Holland (LSH) TKI-LSH-DT2023-LUMC: 2024-02ZonMw (Netherlands Organisation for Health Research and Development) 09120012010061
6 · The paper itself

Abstract

Cancer therapy would benefit from suppressing cancer cell motility in the process of metastasis. Such directed cell migration relies on the propulsive force established by the filamentous actin network within lamellipodia. Proteins of the Ena/VASP family and the WAVE regulatory complex orchestrate lamellar protrusions and therefore provide promising targets for pharmacological interventions. Here, we report a cross-talk between Ena/VASP proteins and WAVE2 that is important for cancer cell extravasation. Mutating the EVH1 domain recognition motif in WAVE2 abrogates chemotaxis of triple-negative MDA-MB-231 breast cancer cells and reduces their extravasation in a zebrafish model. In pilot experiments, orthotopic implantation of these cells into mice led to a reduction in macrometastasis, resulting in prolonged survival. Similarly, intervention by an Ena/VASP-EVH1 inhibitor also reduced metastasis in vivo. Our results suggest that pharmacological interference with the Ena/VASP-WAVE2 interaction may thus reduce metastasis.

Indexed as

Cell Adhesion MoleculesChemotaxisDNA-Binding ProteinsMicrofilament ProteinsWiskott-Aldrich Syndrome Protein FamilyAnimalsCell Line, TumorCell MovementFemaleHumansMiceNeoplasm MetastasisVasodilator-Stimulated PhosphoproteinZebrafishCell Adhesion MoleculesDNA-Binding ProteinsENA-VASP proteinsMicrofilament ProteinsVasodilator-Stimulated PhosphoproteinWiskott-Aldrich Syndrome Protein Familyextravasationmetastasisoncologypharmacologytarget validation

Identifiers

PMID40560613
PMCPMC12232546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.